1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Ophthalmic Therapeutic Drugs: Technologies and Global Markets

Ophthalmic Therapeutic Drugs: Technologies and Global Markets

  • July 2015
  • 111 pages
  • ID: 196569
  • Format: PDF
  • By BCC Research

Summary

Table of Contents

This BCC Research report identifies unmet clinical needs based on existing ophthalmic therapeutic drugs in retinal disease and diabetes related conditions as well exploring potential new markets in the treatment of orphan diseases, retinitis pigmentosa and uveitis. Includes forecasts through 2019.

Use this report to:
- Receive a detailed analysis of the recent advances in ophthalmic therapeutic medicine and its potential impact on the pharmaceutical industry.
- Examine market factors and to identify market potential through 2019.
- Learn about the new developments in ophthalmic therapeutics including novel biologics, formulations and the launch of biosimilars and generics.
- Identify unmet clinical needs based on existing ophthalmic therapeutic drugs.

Highlights
- The global ophthalmic therapeutic drug market was valued at $12.3 billion in 2014. This market is expected to reach $19 billion by 2019, with a compound annual growth rate (CAGR) of 9.1% from 2014 to 2019.
- The global age-related macular degeneration (AMD) market is expected to grow to nearly $7.9 billion by 2019 from nearly $5.4 billion in 2014, a CAGR of 7.8% from 2014 to 2019.
- The global glaucoma therapeutic market generated revenue of $3.8 billion in 2014, and by 2019 this segment is expected to generate $6.4 billion, with a CAGR of 11.1% from 2014 to 2019.

Introduction & Scope

INTRODUCTION

STUDY GOALS AND OBJECTIVES
Around 285 million people are visually impaired worldwide; however, 80% of visual impairment can be prevented, detected or cured. This report provides a comprehensive analysis of the ophthalmic drug market by reviewing recent improvements in diagnosis and advances in product development, novel formulations and delivery devices, and clinical development of new drug classes to treat both the signs and symptoms of prevalent eye conditions. This report also discusses market trends and opportunities based on therapeutic areas and geographical regions. The report’s main focus is to identify unmet clinical needs based on existing ophthalmic therapeutic drugs in retinal disease and diabetes-related conditions as well exploring potential new markets in the treatment of orphan diseases, retinitis pigmentosa and uveitis.

REASONS FOR DOING THE REPORT
The ophthalmic market is dominated by five major companies, Alcon (Novartis), Allergan, Merck & Co, Pfizer and Roche, each vying for pole position in key therapeutic
fields such as age-related macular degeneration (AMD) and glaucoma. Around 60% of global revenues are generated in the U.S.; however, many of the leading agents are
either off-patent or face patent expiry in the next five years. This will allow innovative generic and formulation specialists to generate cost-effective mono and combination
therapies, and force existing companies to develop new classes of drugs to protect their franchises and address areas of unmet clinic needs. According to the

Pharmaceutical Research and Manufacturers of America (PhRMA), there are over 50 drugs in clinical development, including small molecule agents, biopharmaceuticals,
cell and gene-based therapies, many of which target the underlying cause of diseases and not just the symptoms. In 2014, the ophthalmic therapeutic drug market was
worth around $12.3 billion, and this is forecast to rise to over $19 billion by 2019, as the industry focuses on commercially viable targets of high unmet clinical need such as
orphan drugs diseases and the treatment of dry AMD.

SCOPE OF REPORT
This report on ophthalmic therapeutics drugs provides a brief description of the current status of the industry and recent developments. The report analyzes the market trends, and identifies key therapeutic and geographical challenges and rising opportunities in the developed and developing world. Finally, it will provide insights into new
developments into ophthalmic therapeutics including novel biologics, formulations and the launch of biosimilars and generics.

INTENDED AUDIENCE
This report provides a detailed analysis of the recent advances in ophthalmic therapeutic medicine and its potential impact on the pharmaceutical industry; it also
examines the market factors and identifies the market potential through 2019. The study is aimed at the pharmaceutical industry, biotechnology firms, generic
manufacturers and biosimilar manufacturers, as well as formulation specialists and device manufacturers interested in enhancing the development of new and existing
products in this field.

METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary sources were used in preparing this study. This analysis of ophthalmic therapeutic medicine breaks down the market by geography and
therapeutic field, and also analyzes current and potential opportunities for ophthalmic therapeutic drug development. It includes market values from 2013 and forecasts
market revenues through 2019. Primary research involved e-mail correspondence and telephone interviews for each market, category, segment and sub-segment across geographies. We wish to extend our thanks to those who took part in interviews for this report, especially the following,
who gave so generously of their time:
- Gregory D. Kunst, Global Marketing Director, Retina Pharmaceuticals, Alcon Inc., a Novartis Company.
- Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie Pharmaceuticals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($2750)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dental Pain - Pipeline Review, H2 2019

Dental Pain - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Dental Pain - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2019, provides an overview of the Dental Pain (Central Nervous ...

Post-Operative Pain - Pipeline Review, H2 2019

Post-Operative Pain - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Post-Operative Pain - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Pipeline Review, H2 2019, provides an overview of the Post-Operative ...

Opioid-Induced Constipation - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Opioid-Induced Constipation - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020

"Opioid-Induced Constipation - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Opioid-Induced Constipation. ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on